secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0000950170-24-117270
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum receives FDA approval for ORLYNVAH for uUTIs; first product approval
---------------------------------------------------------------------------

- FDA approved ORLYNVAH (oral sulopenem) for uUTIs in adult women with limited/no alternative oral antibiotics.
- Approval based on Phase 3 trials SURE 1 (superior to ciprofloxacin) and REASSURE (non-inferior to Augmentin, statistical superiority).
- ORLYNVAH is first oral penem approved in U.S. and Iterum's first FDA-approved product.
- Company renews efforts for strategic transaction (sale/partnership/license) involving ORLYNVAH to maximize value.
- Approximately 40M uUTI prescriptions annually in U.S.; ~1% resistant to all common oral antibiotics, addressing unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024117270/0000950170-24-117270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024117270/itrm-20241025.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-117270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer